- Acute intermittent porphyria (AIP) is a rare genetic disorder characterized by a deficiency of the enzyme porphobilinogen deaminase (PBGD), which leads to the buildup of toxic porphyrin precursors, causing severe neurological and gastrointestinal symptoms
- The demand for effective AIP treatments is significantly driven by increasing awareness about rare genetic disorders, advancements in genetic testing, and the availability of innovative therapies such as givosiran (Givlaari) and emerging gene therapies
- North America is expected to dominate the acute intermittent porphyria market with 45.6% share due to well-established healthcare infrastructure, supportive regulatory policies, and significant investments in rare disease research and development
- Asia-Pacific is expected to be the fastest-growing region in the acute intermittent porphyria market with a share of 14.2%, driven by rising awareness about rare genetic disorders, improving healthcare infrastructure, and increasing investments in precision medicine
- Urine test segment is expected to dominate the market with a market share of 53.5%, due to its non-invasive nature, cost-effectiveness, and high accuracy in detecting elevated porphyrin levels
